Dr. Mason Marks advises clients on state and federal controlled substance regulation and licensing. He is a law professor at the University of New Hampshire Franklin Pierce School of Law, a Senior Fellow at the Petrie-Flom Center at Harvard Law School, and an affiliated fellow at the Information Society Project at Yale Law School.
A resident of Portland, Oregon, Mason divides his time between New England and the Pacific Northwest. He enjoys travel, hiking, and exploring the Oregon wilderness.
This article was first published yesterday on Harvard Law School’s Petrie-Flom Center Bill of Health Blog. On Tuesday, Washington State legislators filed SB 5660, a bill that would legalize the supported adult use of psilocybin by people 21 years of age and older. Washington Psilocybin Services Wellness and Opportunity Act Sponsored by Senators Jesse Salomon and Liz Lovelett,
Public and scientific interest in psychedelics such as psilocybin and MDMA is expanding. Once off-limits because of federal prohibition, a trickle of research from the 1990s has grown into a stream. But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Psilocybin, a
On March 18, Governor Kate Brown appointed members to the Oregon Psilocybin Advisory Board, which held its first meeting on March 31. Since then, the Board has met monthly and created five subcommittees to study facets of the emerging psilocybin industry including research, equity, manufacturing, training, and licensing. I chair the Licensing Subcommittee, which focuses
